Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
暂无分享,去创建一个
Ross T Tsuyuki | F. McAlister | S. Majumdar | Jeffrey A. Johnson | R. Tsuyuki | D. Eurich | Finlay A McAlister | Sumit R Majumdar | Jeffrey A Johnson | Dean T Eurich
[1] Cindy Farquhar,et al. 3 The Cochrane Library , 1996 .
[2] F. Holleman,et al. Metformin and lactic acidosis: cause or coincidence? A review of case reports , 2004, Journal of internal medicine.
[3] H. Krumholz,et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. , 1998, JAMA.
[4] R. Gansevoort,et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review , 2004 .
[5] Neil R. Powe,et al. Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.
[6] A. Laupacis,et al. Observational Studies of Treatment Effectiveness: Some Cautions , 2004, Annals of Internal Medicine.
[7] R. Pauwels,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.
[8] J. Levy,et al. U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.
[9] M Maclure,et al. Use of comorbidity scores for control of confounding in studies using administrative databases. , 2000, International journal of epidemiology.
[10] P. Grant. The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes , 1996, Diabetes Care.
[11] R. DeFronzo,et al. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.
[12] R. Rothman,et al. Frequency of inappropriate metformin prescriptions. , 2002, JAMA.
[13] M. Tonelli,et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. , 2004, Journal of the American College of Cardiology.
[14] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[15] W. Hundley,et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. , 2004, Diabetes care.
[16] S. Majumdar,et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. , 2002, Diabetes care.
[17] R. Misbin. The phantom of lactic acidosis due to metformin in patients with diabetes. , 2004, Diabetes care.
[18] J. Lalau,et al. Lactic Acidosis in Metformin-Treated Patients , 1999 .
[19] J. Lalau,et al. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. , 1999, Drug safety.
[20] M. Nichaman,et al. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. , 2000, Archives of internal medicine.
[21] A. Holstein,et al. Contra‐indications to metformin therapy are largely disregarded , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[22] P. Armstrong,et al. Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.
[23] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[24] N. Day,et al. Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.
[25] Ross T Tsuyuki,et al. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. , 2004, Diabetes care.
[26] G. Nichols,et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. , 2001, Diabetes care.
[27] G. McEvoy,et al. AHFS Drug Information , 1994 .
[28] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[29] E. Cerasi,et al. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? , 1996, Diabetologia.
[30] H. Krumholz,et al. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.
[31] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[32] C. Meinert,et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.
[33] G. Nichols,et al. Replicating the chronic disease score (CDS) from automated pharmacy data. , 1994, Journal of clinical epidemiology.
[34] P. Armstrong,et al. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. , 2004, Clinical therapeutics.
[35] H. Krumholz,et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. , 2003, JAMA.
[36] Gregory E. Simon,et al. A Chronic Disease Score with Empirically Derived Weights , 1995, Medical care.
[37] Pierre Ernst,et al. The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .
[38] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[39] E H Wagner,et al. A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.
[40] W. Kannel,et al. Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.
[41] E. Salpeter,et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.
[42] N. Lamblin,et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.
[43] The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. , 1975, Diabetes.